Right patient, right dose, right time

 

 

While artificial intelligence (AI) has shown promising potential, much of its use has remained theoretical or retrospective. Turning its potential into real-world healthcare outcomes, researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have successfully utilised an AI platform to make precise recommendations for dose adjustments in 10 patients at the National University Cancer Institute, Singapore (NCIS) in Singapore. 

Led by Professor Dean Ho, Director of the Institute for Digital Medicine (WisDM), NUS Medicine (Joint Professor at Department of Pharmacology), the team tracked the cancer biomarkers, CEA and CA125, of 10 patients in Singapore who were diagnosed with advanced solid tumours, to create personalised ‘digital twins’ for each patient.  

By analysing the changes in biomarkers in response to different drug doses, precise recommendations were made to adjust each patient’s treatment plan. Over the period from the first dosing in August 2020 to the last dosing in September 2022, clinicians accepted 97.2 per cent of the recommended doses, with some patients receiving optimal doses that were approximately 20 per cent lower on average. The research trial marks a potential shift towards personalised oncology, where drug doses are dynamically adjusted for each patient during treatment, potentially reducing costs, rather than adhering to a standard, one-size-fits-all treatment regimen. 

This approach to patient care is enabled by the CURATE.AI platform—developed by Prof Ho and team—an optimisation platform which harnesses a patient’s clinical data, such as drug type, drug dose and cancer biomarkers, to generate an individualised digital profile to determine a customised optimal dose during chemotherapy treatment.

Full article: https://medicine.nus.edu.sg/news/right-patient-right-dose-right-time/